AES Accelerated Enrollment Solutions

VACCINES EXPERTISE

Vaccines can target a wide range of **pandemic threats** (such as Ebola and influenza), **emerging diseases** (such as Zika and Eastern equine encephalitis [EEE] viruses), other serious **infections** (HIV, streptococcus, malaria) and **bioterrorism threats** (smallpox, anthrax).

Influenza is by far the leading target indication in vaccine development, followed distantly by malaria, respiratory syncytial virus (RSV), hepatitis B, and neisseria meningitidis, among many others.

Named Best Clinical Trial Network at the 2019 Vaccine Industry Excellence (ViE) Awards, AES Sites & Patients has a global site footprint including 75+ sites in the U.S., Latin America, Europe, South Africa and India.

AES EXPERIENCE

Therapeutic area: **Vaccines**
Number of trials: **1000+**
Number of subjects randomized: **72,000+**
Average subject retention rate: **98%**
Number of COVID-19 trials: **18** (and counting)
Number of COVID-19 subjects randomized: **16,000+**

Experience in 30+ vaccine indications – from Anthrax to Zika

INSIGHTS

- Vaccine trials run at a very aggressive pace and tend to enroll many subjects (healthy adult volunteers age 18+) in a short time.
- Seasonal outbreak dependency narrows enrollment periods for large patient volumes.
- Vaccine trials have workload peaks and valleys that are much more pronounced than most clinical trials. Surge capacity is required for high throughput studies.
- Retention rates are critical; it may be necessary to offer end-of-study retention incentives to keep patients in a study.
- The study endpoints may include Peripheral Blood Mononuclear Cells (PBMCs). The process for isolating PBMCs is labor-intensive, requiring immune white blood cell isolation and freezing capabilities. AES Sites & Patients has 7 onsite U.S. labs with PBMC capabilities – that are able to work under internal or sponsor-specific SOPs and have been engaged with government-funded vaccine trials requiring approved Quality Management Plans.